title: Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
abstract: BACKGROUND
  Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.
  
  
  METHODS
  Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect.At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing.
  
  
  CONCLUSIONS
  We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.
authors: Centre for Pulmonary Hypertension, University Medical Centre Hamburg - Eppendorf, 20246 Hamburg, Germany.
authors: Jan K
authors: JK
authors: Hennigs
authors: Gunhild
authors: G
authors: Keller
authors: Hans Jörg
authors: HJ
authors: Baumann
authors: Friedemann
authors: F
authors: Honecker
authors: Stefan
authors: S
authors: Kluge
authors: Carsten
authors: C
authors: Bokemeyer
authors: Tim H
authors: TH
authors: Brümmendorf
authors: Hans
authors: H
authors: Klose
references: Respiration. 2008;76(3):295-302
references: 18160817
references: J Clin Oncol. 2007 Sep 1;25(25):3908-14
references: 17761974
references: Ann Intern Med. 2006 Jul 18;145(2):152-3
references: 16847299
references: Blood. 2007 Dec 1;110(12):4055-63
references: 17720881
references: N Engl J Med. 2004 Sep 30;351(14):1425-36
references: 15459304
references: J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54
references: 19555858
references: N Engl J Med. 2005 Sep 29;353(13):1412-3
references: 16192491
references: Chest. 2007 Dec;132(6):2057-8; author reply 2058
references: 18079249
references: Bone Marrow Transplant. 2009 Jun;43(12):967-8
references: 19104491
references: Thorax. 2006 Aug;61(8):736
references: 16877696
references: Am J Med Sci. 2001 Apr;321(4):292-9
references: 11307870
references: Leuk Res. 2009 Jun;33(6):861-4
references: 18986702
references: Chest. 2009 Jun;135(6):1462-1469
references: 19188548
references: Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7
references: 20581169
references: J Clin Invest. 2005 Oct;115(10):2811-21
references: 16200212
references: Eur Respir J. 2009 Dec;34(6):1219-63
references: 19749199
references: Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8
references: 17600277